In addition, CML or pentosidine treatments also elevated NF-κB p50/65 DNA binding activity in A549 and Calu-6 cells, which supported the activation of NF-κB. This evidence concerns the gene NFKB1 and chronic myelogenous leukemia, BCR-ABL1 positive.